The Cheeky Study: A Novel Delivery System for CAB-RPV LA

Inclusion Criteria:

• Age 18 years or older

• Male sex at birth and gender identity other than male

• Willing and able to provide written informed consent

• HIV-infected, confirmed by laboratory testing (can be via medical record)

• Eligible to receive CAB-RPV LA per FDA-approved label

• Virologically suppressed at the last visit within the last 6 months (HIV RNA <50copies/ml)

• Interested in initiating CAB-RPV LA for HIV treatment and willing to receiveinjections at Bridge HIV

• Currently receiving HIV care by a care provider at one of the collaborating primarycare clinics.

• Has a cell phone and active service

• Able to understand, read, and speak English

Exclusion Criteria:

• Unable to receive gluteal injections

• Plans to move away from the site area within the next 9 months.

• History of known or suspected drug resistance that would compromise the CAB-RPVregimen

• Rilpivirine: L100I; K101E; V106I and A; V108I; E138K and A, G, Q, R; V179F andI; Y181C and I; V189I; G190E; H221Y and H/L; F227C; and M230I and L;K103N+K238T, K103N+E138G+K238T; Y188L

• Cabotegravir: Q146L; S153Y; I162M; T124A; Q148H, K; C56S; V72I; L74M; V75A;T122N; E138K; G140S; G149A; M154I; and N155H

• Prior hypersensitivity to cabotegravir or rilpivirine

• Current or expected use of any of the following medications:

• Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin

• Antimycobacterials: rifabutin, rifampin, rifapentine

• Systemic glucocorticoids: more than a single dose of dexamethasone

• Herbal: St John's Wort

• Any medical, psychiatric, or social condition or other responsibilities that, in thejudgment of the investigator, would make participation in the study unsafe,complicate interpretation of study outcome data, or otherwise interfere withachieving the study objectives